No Data
No Data
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
Express News | Cidara Therapeutics Strengthens Its Scientific Advisory Board With Infectious Disease Experts
H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24
H.C. Wainwright analyst Ed Arce maintains $Cidara Therapeutics(CDTX.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 44.0%
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $24 Price Target
Cidara Cutting 30% of Workforce to Focus on CD388 for Influenza
Express News | Cidara Therapeutics Inc: Expects to Initiate Phase 2B Clinical Trial of Cd388 for Prevention of Influenza in Q3 2024